News

Sunovion Submits New Drug Application to the FDA for Apomorphine Sublingual Film for the Treatment of OFF Episodes Associated with PD

(March 30, 2018) – Sunovion Pharmaceuticals Inc. today announced that it has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) on March 29, 2018, for apomorphine sublingual film (APL-130277) to treat motor fluctuations (OFF episodes) experienced by people living with Parkinson’s disease (PD). Read more

Follow Us Follow us on TwitterFollow us on FacebookInstagram

Sign Up for Email Alerts

By providing your email you agree to receive periodic emails from The Parkinson Alliance.

Please tell us more about yourself:

Contact UsTerms Of UsePrivacy Policy

The Parkinson Alliance is a nonprofit, tax-exempt charitable organization under section 501(c)(3) of the Internal Revenue Code. Donations are tax-deductible as allowed by law. Copyright © 2018 The Parkinson Alliance. All rights reserved.